Incyte Corp

NASDAQ: INCY
$83.38
+$1.04 (+1.3%)
Closing Price on November 8, 2024

INCY Articles

Gilead Sciences has long been in need of a catalyst to move its business, and a lot of investors and analysts alike have considered this company dead money until something happens.
24/7 Wall St. has put together a preview of Express Scripts, T-Mobile and some of the other most anticipated quarterly earnings reports that are on deck for Tuesday.
Shares of Calithera Biosciences saw a solid gain early on Monday after the company reported a global collaboration and licensing agreement with Incyte.
Credit Suisse sees future earnings growth from Incyte’s pipeline, with epacadostat’s potential as a best-in-class immunotherapy combination agent making the stock an attractive takeout target.
Stocks have pulled back off their highs from the end of 2016 and that Dow Jones Industrial Average (DJIA) 20,000 mark remains elusive. The major market indexes were indicated a tad lower on Monday,...
Needless to say, the past two years have been rough on biotech. The question for investors is which of the stocks hold the best potential in 2017.
A new Jefferies research report makes the case that five top biotech companies may be right in the cross-hairs of the biotech giants or perhaps large pharmaceutical companies.
In a new research report, Baird notes two biotech companies in its research coverage universe that may be considered speculative takeover targets, and a third is a possible target as well.
The Jefferies Healthcare Conference wrapped up in New York City last week, and the mood was reported as generally positive, with investors feeling much better than a few months ago.
Despite a modest erosion to fundamentals and sector headwinds, Jefferies does not anticipate any dramatic earnings misses, which could help sentiment continue to turn around.
FDA rulings can make or break some companies. 24/7 Wall St. has collected eight key FDA decisions coming up in 2016 or 2017.
The top analyst upgrades, downgrades and initiations seen on Wednesday, March 23, include Charles Schwab, Dean Foods, HollyFrontier, Incyte, Newfield Exploration and Nike.
Despite the market rally, insiders are still buying at big levels, while insider selling remains dormant. This is a very positive sign for equity investors and the market as a whole.
These biotech companies 24/7 Wall St. has picked stood out from the rest with big moves over the course of last week.
Incyte reported better-than-expectged fourth-quarter financial results after the markets closed on Wednesday.